Hair loss hope: new supplement trial for women begins
NCT ID NCT07347145
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests a daily supplement called Olistic Next Women in 60 women aged 45-65 who are starting to lose hair. For 6 months, some women get the supplement and others get a placebo. Researchers will measure hair density and shedding to see if the supplement helps without causing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female subjects with female pattern hair loss * 45-65 years * Signed informed consent * The study participant is in good general condition for her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study. Exclusion Criteria: * Known or documented intolerance/allergy to any of the ingredients of the study product * Chronic wounds, erosions, pre-existing infected skin or inflammation in the study area * Suspected non-compliance * Late onset acne * Hirsutism * Any systemic immunosuppressant given within the 12 months prior to the study (e.g. systemic Prednisolone in high doses, Azathioprine, Metothrexate etc.) * Locally (in the study area) applied products/medicaments which in the opinion of the investigator could lead to an influence of the study results (e.g. topical minoxidil, caffeine etc.) * Systemically administered products and medicaments which in the opinion of the investigator could lead to an influence of the study results (e.g. hormone-influencing medicaments, medicaments which frequently lead to hypertrichosis or hair loss etc.) * Subjects receiving stable hormone replacement therapy (HRT) for \<6 months prior to screening will be excluded. * Subjects who follow an exclusively or mainly vegan diet * Known or documented Gluten intolerance * Lactose intolerance * Hyperthyroidism * Subjects with hypothyroidism with non-stable thyroid-stimulating hormone (TSH) levels will be excluded. * Other diseases of the scalp which in the opinion of the investigator could lead to an influence of the study results (e.g. Lichen planus, Psoriasis capitis, scarring alopecia etc.) * Participation in a clinical trial/study * Participation in a clinical trial/study within the last 30 days * Deviations from the norm in the following laboratory values in the blood test of the screening visit: zinc, ferritin, selenium, folic acid, vitamin B12, TSH, and CRP. (Only at Baseline)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early female pattern hair loss (FPHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CentroDerm
Wuppertal, Barmen, 42287, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.